Eli Lilly & Co. (NYSE:LLY) announced that it has received U.S. Food and Drug Administration approval for Cymbalta for the management of fibromyalgia, a chronic pain disorder.
Cymbalta (duloxetine HCl) is the first serotonin-norepinephrine reuptake inhibitor that has proven effective in the treatment of pain associated with fibromyalgia. The new approved indication becomes the fourth FDA approved use of the drug. Cymbalta has been previously approved for management of diabetic peripheral neuropathic pain (DPNP), the treatment of major depressive disorder and generalized anxiety disorder.
"The approval of Cymbalta is important because it provides physicians and patients with a new treatment option shown to help reduce pain and improve functioning in this difficult-to-treat disorder," said Madelaine Wohlreich, M.D., medical advisor and research physician at Lilly.
"The FDA approval of Cymbalta for the management of fibromyalgia is another important step in the efforts to ensure that people with fibromyalgia will have the availability of effective medications to help reduce the chronic, widespread pain of this life-altering disorder," said Lynne Matallana, president of the National Fibromyalgia Association and a fibromyalgia patient.
[Source: Medical News Today]
Comment Preview